Is Sage Therapeutics a good buy?
Sage Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.50, and is based on 8 buy ratings, 8 hold ratings, and no sell ratings.
How many employees does Sage therapeutics have?
637 employees
Who owns Sage Therapeutics?
SAGE Therapeutics Inc (NASDAQ:SAGE) The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
What does Zulresso do?
Zulresso and Lexapro are approved by the Food and Drug Administration (FDA) to treat different conditions. Zulresso is approved to treat postpartum depression (PPD) in adults. Lexapro is approved to treat major depressive disorder in people ages 12 years and older.
When was Sage Therapeutics founded?
2010
Does insurance cover Zulresso?
Brexanolone (Zulresso) is considered investigational and therefore not covered when the above criteria are not met. Zulresso treatment carries a black box warning for risk of excessive sedation or sudden loss of consciousness during administration.
Where can I get Zulresso?
Because of the risk of serious harm resulting from feeling very sleepy or passing out during treatment, ZULRESSO is only available through a restricted program called the ZULRESSO REMS in which a healthcare provider will carefully monitor you at a certified healthcare facility.
How much is Zulresso?
Zulresso will likely cost an average of $7,450 per vial, for a total cost of $34,000 without insurance. Postpartum Depression: What Is Postpartum Depression?
What do they give you for postpartum?
The class of medications prescribed for postpartum depression is known as selective serotonin-reuptake inhibitors (SSRIs), which includes fluoxetine and sertraline. Also effective is venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI).
What class of drug is Brexanolone?
Brexanolone, a neuroactive steroid gamma-aminobutyric acid (GABA)A receptor–positive modulator, was granted a priority review and was designated a breakthrough treatment by the FDA.
Who makes Zulresso?
Our Medicine Zulresso™ (brexanolone) injection CIV | Sage Therapeutics.
Is Brexanolone a controlled substance?
Brexanolone is chemically known as 3α-hydroxy-5α-pregnan-20-one and is also referred to as allopregnanolone. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a recommendation that brexanolone be placed in schedule IV of the Controlled Substances Act (CSA).
How is Brexanolone administered?
Brexanolone is administered as a continuous IV infusion over a total period of 60 hours, during approximately 2.5 days. The prescribed dosing regimen is as follows: 0 to -4 hours: Start with a dose of 30 mcg/kg/hour. 4 to 24 hours: Increase the dose to 60 mcg/kg/hour.
Which adverse effect has been associated with use of Cenobamate?
The most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, and headache.
What is Brexanolone used for?
Brexanolone is a medication used in the treatment of postpartum depression in adult women. It is in the GABA-A modulator class of medications.
Which potentially serious adverse effect is associated with Tenapanor?
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients [see ADVERSE REACTIONS]. If severe diarrhea occurs, suspend dosing and rehydrate patient.